SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

08 Nov 2022 Evaluate
With no major difference for the quarter endedSeptember 2022 , the total revenue stood at Rs. 8288.70  millions.The Company to register a -48.11%  fall in the net profit for the quarter ended September 2022.The Operating Profit of the company witnessed a decrease to 1645.30 millions from 1717.60 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202209 202109 % Var
Sales 8288.70 8026.20 3.27 8288.70 8026.20 3.27 8288.70 8026.20 3.27
Other Income 1177.00 609.00 93.27 1177.00 609.00 93.27 1177.00 609.00 93.27
PBIDT 1645.30 1717.60 -4.21 1645.30 1717.60 -4.21 1645.30 1717.60 -4.21
Interest 285.60 151.10 89.01 285.60 151.10 89.01 285.60 151.10 89.01
PBDT 1290.10 1566.50 -17.64 1290.10 1566.50 -17.64 1290.10 1566.50 -17.64
Depreciation 471.10 375.40 25.49 471.10 375.40 25.49 471.10 375.40 25.49
PBT 819.00 1191.10 -31.24 819.00 1191.10 -31.24 819.00 1191.10 -31.24
TAX 345.70 278.90 23.95 345.70 278.90 23.95 345.70 278.90 23.95
Deferred Tax 244.50 18.70 1207.49 244.50 18.70 1207.49 244.50 18.70 1207.49
PAT 473.30 912.20 -48.11 473.30 912.20 -48.11 473.30 912.20 -48.11
Equity 11933.20 9946.00 19.98 11933.20 9946.00 19.98 11933.20 9946.00 19.98
PBIDTM(%) 19.85 21.40 -7.24 19.85 21.40 -7.24 19.85 21.40 -7.24

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×